Search

Your search keyword '"Visser, Otto J."' showing total 41 results
Start Over Author "Visser, Otto J."
41 results on '"Visser, Otto J."'

1. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

Author

Brink, Mirian, primary, Huisman, Francien, additional, Meeuwes, Frederik Okko, additional, van der Poel, Marjolein W.M, additional, Kersten, Marie José, additional, Wondergem, Marielle J, additional, Bohmer, Lara H., additional, Woei-A-Jin, F.J. Sherida H., additional, Visser, Otto J., additional, Oostvogels, Rimke, additional, Jansen, Patty M, additional, Diepstra, Arjan, additional, Snijders, Tjeerd J.F., additional, Huls, Gerwin A, additional, Vermaat, Joost S.P., additional, Plattel, Wouter J., additional, and Nijland, Marcel, additional

Published
2024
Full Text
View/download PDF

2. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning

Author

Aydin, Mesire, primary, de Leeuw, David C., additional, Rutten, Caroline E., additional, Visser, Otto J., additional, Tang, Man Wai, additional, van Roessel, Cinthy, additional, Janssen, Jeroen J. W., additional, Biemond, Bart J., additional, van de Loosdrecht, Arjan A., additional, Hazenberg, Mette D., additional, Meijer, Ellen, additional, and Nur, Erfan, additional

Published
2023
Full Text
View/download PDF

3. Supplemental Tables S1-2 from A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma

Author

de Baaij, Laura R., primary, Berkhof, Johannes, primary, van de Water, Jolanda M.W., primary, Sieniawski, Michal K., primary, Radersma, Marijn, primary, Verbeek, Wieke H.M., primary, Visser, Otto J., primary, Oudejans, Joost J., primary, Meijer, Chris J.L.M., primary, Mulder, Chris J.J., primary, Lennard, Anne L., primary, and Cillessen, Saskia A.G.M., primary

Published
2023
Full Text
View/download PDF

5. Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Author

de Jonge, A.Vera, primary, Duetz, Carolien, additional, Bruins, Wassilis S.C., additional, van Werkhoven, Erik D., additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, de Heer, Koen, additional, Klerk, Clara P.W., additional, Sandberg, Yorick, additional, Fijnheer, Rob, additional, Mutseaers, Pim, additional, Issa, Djamila E., additional, Böhmer, Lara H., additional, Van Kampen, Roel J.W., additional, Visser, Otto J., additional, de Jong, Daphne, additional, Zijlstra, Josée M., additional, Mutis, Tuna, additional, and Chamuleau, Martine E.D., additional

Published
2022
Full Text
View/download PDF

6. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19:an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., Franken, B., de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., and Franken, B.

Abstract

Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied in patients with cancer and COVID-19. Methods: The Dutch Oncology COVID-19 Consortium registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g. do-not-intubate codes) were studied in relation to COVID-19 outcomes in patients with cancer. Oncological treatment restrictions were not taken into account. Results: Between 27th March 2020 and 4th February 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anticancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g. do-not-intubate codes). Most identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome. Conclusion: There was no evidence of a negative impact of anticancer therapies on COVID-19 outcomes. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.

Published
2022

7. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., Bakker, S. D., MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., and Bakker, S. D.

Published
2022

8. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, primary, Tol, Jolien, additional, Hamberg, Paul, additional, Cloos, Marissa, additional, Kastelijn, Elisabeth A., additional, Borgers, Jessica S.W., additional, Nuij, Veerle J.A.A., additional, Klaver, Yarne, additional, Herder, Gerarda J.M., additional, Mutsaers, Pim G.N.J., additional, Dumoulin, Daphne W., additional, Oomen-de Hoop, Esther, additional, van Diemen, Nico G.J., additional, Libourel, Eduard J., additional, Geraedts, Erica J., additional, Bootsma, Gerben P., additional, van der Leest, Cor H., additional, Peerdeman, Anne L., additional, Herbschleb, Karin H., additional, Visser, Otto J., additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, de Vries, Elisabeth G.E., additional, Hendriks, Lizza E.L., additional, Beerepoot, Laurens V., additional, Westgeest, Hans M., additional, van den Berkmortel, Franchette W.P.J., additional, Haanen, John B.A.G., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, Becker-Commissaris, A., additional, Terheggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Strobbe, L., additional, Koekkoek, J.A.F., additional, Brocken, P., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, van 't Westeinde, S.C., additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, and van Geffen, W.H., additional

Published
2022
Full Text
View/download PDF

9. First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study

Author

Meeuwes, Frederik O., primary, Brink, Mirian, additional, Van Der Poel, Marjolein W.M., additional, Kersten, Marie José, additional, Wondergem, Mariëlle, additional, Mutsaers, Pim G.N.J., additional, Böhmer, Lara H., additional, Woei-a-Jin, F.J. Sherida H., additional, Visser, Otto J., additional, Oostvogels, Rimke, additional, Jansen, Patty M., additional, Neelis, Karen J., additional, Crijns, Anne P.G., additional, Daniëls, Laurien A., additional, Vermaat, Joost S.P., additional, Huls, Gerwin A., additional, and Nijland, Marcel, additional

Published
2021
Full Text
View/download PDF

14. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

MS Medische Oncologie, Cancer, Infection & Immunity, Longziekten, de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Loenhout, C. J., van der Leest, C. H., Becker-Commissaris, A., Borgers, J. S.W., Terhegggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Klaver, Y., Hamberg, A. P., Libourel, E. J., Strobbe, L., Cloos, M., Geraedts, E. J., Drooger, J. C., Heller, R., de Groot, J. W.B., Stigt, J. A., Nuij, V. J.A.A., Pitz, C. C.M., Slingerland, M., Borm, F. J., Haberkorn, B. C.M., Westeinde, S. C.van t., Aarts, M. J.B., van Putten, J. W.G., Youssef, M., Cirkel, G. A., Herder, G. J.M., van Rooijen, C. R., Citgez, E., Barlo, N. P., Scholtes, B. M.J., Koornstra, R. H.T., Claessens, N. J.M., Faber, L. M., Rikers, C. H., van de Wetering, R. A.W., Veurink, G. L., Bouter, B. W., Houtenbos, I., Bard, M. P.L., Herbschleb, K. H., Kastelijn, E. A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T. J.N., Schuurbiers-Siebers, O. C.J., Suijkerbuijk, K. P.M., van Lindert, A. S.R., van de Wouw, A. J., van den Boogaart, V. E.M., Bakker, S. D., Looysen, E., Peerdeman, A. L., de Jong, W. K., Siemerink, E. J.M., Staal, A. J., Franken, B., van Geffen, W. H., Bootsma, G. P., MS Medische Oncologie, Cancer, Infection & Immunity, Longziekten, de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Loenhout, C. J., van der Leest, C. H., Becker-Commissaris, A., Borgers, J. S.W., Terhegggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Klaver, Y., Hamberg, A. P., Libourel, E. J., Strobbe, L., Cloos, M., Geraedts, E. J., Drooger, J. C., Heller, R., de Groot, J. W.B., Stigt, J. A., Nuij, V. J.A.A., Pitz, C. C.M., Slingerland, M., Borm, F. J., Haberkorn, B. C.M., Westeinde, S. C.van t., Aarts, M. J.B., van Putten, J. W.G., Youssef, M., Cirkel, G. A., Herder, G. J.M., van Rooijen, C. R., Citgez, E., Barlo, N. P., Scholtes, B. M.J., Koornstra, R. H.T., Claessens, N. J.M., Faber, L. M., Rikers, C. H., van de Wetering, R. A.W., Veurink, G. L., Bouter, B. W., Houtenbos, I., Bard, M. P.L., Herbschleb, K. H., Kastelijn, E. A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T. J.N., Schuurbiers-Siebers, O. C.J., Suijkerbuijk, K. P.M., van Lindert, A. S.R., van de Wouw, A. J., van den Boogaart, V. E.M., Bakker, S. D., Looysen, E., Peerdeman, A. L., de Jong, W. K., Siemerink, E. J.M., Staal, A. J., Franken, B., van Geffen, W. H., and Bootsma, G. P.

Published
2020

15. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

de Joode, Karlijn, primary, Dumoulin, Daphne W., additional, Tol, Jolien, additional, Westgeest, Hans M., additional, Beerepoot, Laurens V., additional, van den Berkmortel, Franchette W.P.J., additional, Mutsaers, Pim G.N.J., additional, van Diemen, Nico G.J., additional, Visser, Otto J., additional, Oomen-de Hoop, Esther, additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, Hendriks, Lizza E.L., additional, Haanen, John B.A.G., additional, de Vries, Elisabeth G.E., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, van Loenhout, C.J., additional, van der Leest, C.H., additional, Becker-Commissaris, A., additional, Borgers, J.S.W., additional, Terhegggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Klaver, Y., additional, Hamberg, A.P., additional, Libourel, E.J., additional, Strobbe, L., additional, Cloos, M., additional, Geraedts, E.J., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Nuij, V.J.A.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, Westeinde, S.C. van 't, additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, Herder, G.J.M., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Herbschleb, K.H., additional, Kastelijn, E.A., additional, Brocken, P., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, Peerdeman, A.L., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, van Geffen, W.H., additional, and Bootsma, G.P., additional

Published
2020
Full Text
View/download PDF

18. Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients

Author

Caram-Deelder, Camila, Kreuger, Aukje L, Evers, Dorothea, de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, Zwaginga, Jaap Jan, van der Bom, Johanna G, Middelburg, Rutger A., Caram-Deelder, Camila, Kreuger, Aukje L, Evers, Dorothea, de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, Zwaginga, Jaap Jan, van der Bom, Johanna G, and Middelburg, Rutger A.

Published
2017

19. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort : Role of chemotherapy

Author

Teepen, Jop C., Kremer, Leontien C M, Ronckers, Cecile M., van Leeuwen, Flora E., Hauptmann, Michael, Van Dulmen-Den Broeder, Eline, Van Der Pal, Helena J., Jaspers, Monique W, Tissing, Wim J., Van Den Heuvel-Eibrink, Marry M., Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, Visser, Otto J, Neggers, Sebastian J C M M, van der Heiden-van der Loo, Margriet, Teepen, Jop C., Kremer, Leontien C M, Ronckers, Cecile M., van Leeuwen, Flora E., Hauptmann, Michael, Van Dulmen-Den Broeder, Eline, Van Der Pal, Helena J., Jaspers, Monique W, Tissing, Wim J., Van Den Heuvel-Eibrink, Marry M., Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, Visser, Otto J, Neggers, Sebastian J C M M, and van der Heiden-van der Loo, Margriet

Published
2017

20. Absence of the spleen and the occurrence of primary red cell alloimmunization in humans

Author

Evers, Dorothea, van der Bom, Johanna G, Tijmensen, Janneke, de Haas, Masja, Middelburg, Rutger A., de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, Zwaginga, Jaap Jan, Evers, Dorothea, van der Bom, Johanna G, Tijmensen, Janneke, de Haas, Masja, Middelburg, Rutger A., de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, and Zwaginga, Jaap Jan

Published
2017

21. Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients

Author

CDL Staf Patiëntenzorg KC, Other research (not in main researchprogram), Caram-Deelder, Camila, Kreuger, Aukje L, Evers, Dorothea, de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, Zwaginga, Jaap Jan, van der Bom, Johanna G, Middelburg, Rutger A., CDL Staf Patiëntenzorg KC, Other research (not in main researchprogram), Caram-Deelder, Camila, Kreuger, Aukje L, Evers, Dorothea, de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, Zwaginga, Jaap Jan, van der Bom, Johanna G, and Middelburg, Rutger A.

Published
2017

22. Absence of the spleen and the occurrence of primary red cell alloimmunization in humans

Author

CDL Staf Patiëntenzorg KC, Other research (not in main researchprogram), Evers, Dorothea, van der Bom, Johanna G, Tijmensen, Janneke, de Haas, Masja, Middelburg, Rutger A., de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, Zwaginga, Jaap Jan, CDL Staf Patiëntenzorg KC, Other research (not in main researchprogram), Evers, Dorothea, van der Bom, Johanna G, Tijmensen, Janneke, de Haas, Masja, Middelburg, Rutger A., de Vooght, Karen M K, van de Kerkhof, Daan, Visser, Otto J, Péquériaux, Nathalie C V, Hudig, Francisca, and Zwaginga, Jaap Jan

Published
2017

23. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: Role of chemotherapy

Author

PMC Medisch specialisten, PMC Research, Zorg en O&O, UMC Utrecht, Haematologie patientenzorg, Child Health, Teepen, Jop C., Kremer, Leontien C M, Ronckers, Cecile M., van Leeuwen, Flora E., Hauptmann, Michael, Van Dulmen-Den Broeder, Eline, Van Der Pal, Helena J., Jaspers, Monique W, Tissing, Wim J., Van Den Heuvel-Eibrink, Marry M., Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, Visser, Otto J, Neggers, Sebastian J C M M, van der Heiden-van der Loo, Margriet, PMC Medisch specialisten, PMC Research, Zorg en O&O, UMC Utrecht, Haematologie patientenzorg, Child Health, Teepen, Jop C., Kremer, Leontien C M, Ronckers, Cecile M., van Leeuwen, Flora E., Hauptmann, Michael, Van Dulmen-Den Broeder, Eline, Van Der Pal, Helena J., Jaspers, Monique W, Tissing, Wim J., Van Den Heuvel-Eibrink, Marry M., Loonen, Jacqueline J, Bresters, Dorine, Versluys, Birgitta, Visser, Otto J, Neggers, Sebastian J C M M, and van der Heiden-van der Loo, Margriet

Published
2017

24. ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2

Author

Cillessen, Saskia A G M, Hijmering, Nathalie J, Moesbergen, Laura M, Vos, Wim, Verbrugge, Sue Ellen, Jansen, Gerrit, Visser, Otto J, Oudejans, Joost J, Meijer, Chris J L M, Cillessen, Saskia A G M, Hijmering, Nathalie J, Moesbergen, Laura M, Vos, Wim, Verbrugge, Sue Ellen, Jansen, Gerrit, Visser, Otto J, Oudejans, Joost J, and Meijer, Chris J L M

Published
2015

25. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

Author

Bilgin, Yavuz M., Visser, Otto J, Beckers, Erik A M, Te Boome, Liane CJ, Huisman, Cynthia, Ypma, Paula F., Croockewit, Alexandra J., Netelenbos, Tanja, Kramer, Ellen PA, de Greef, Georgine E, Bilgin, Yavuz M., Visser, Otto J, Beckers, Erik A M, Te Boome, Liane CJ, Huisman, Cynthia, Ypma, Paula F., Croockewit, Alexandra J., Netelenbos, Tanja, Kramer, Ellen PA, and de Greef, Georgine E

Published
2015

26. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

Author

Other research (not in main researchprogram), Externen Hematologie, Bilgin, Yavuz M., Visser, Otto J, Beckers, Erik A M, Te Boome, Liane CJ, Huisman, Cynthia, Ypma, Paula F., Croockewit, Alexandra J., Netelenbos, Tanja, Kramer, Ellen PA, de Greef, Georgine E, Other research (not in main researchprogram), Externen Hematologie, Bilgin, Yavuz M., Visser, Otto J, Beckers, Erik A M, Te Boome, Liane CJ, Huisman, Cynthia, Ypma, Paula F., Croockewit, Alexandra J., Netelenbos, Tanja, Kramer, Ellen PA, and de Greef, Georgine E

Published
2015

27. ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2

Author

CDL Klinisch Chemici in opleiding, Pathologie Pathologen staf, Other research (not in main researchprogram), Cillessen, Saskia A G M, Hijmering, Nathalie J, Moesbergen, Laura M, Vos, Wim, Verbrugge, Sue Ellen, Jansen, Gerrit, Visser, Otto J, Oudejans, Joost J, Meijer, Chris J L M, CDL Klinisch Chemici in opleiding, Pathologie Pathologen staf, Other research (not in main researchprogram), Cillessen, Saskia A G M, Hijmering, Nathalie J, Moesbergen, Laura M, Vos, Wim, Verbrugge, Sue Ellen, Jansen, Gerrit, Visser, Otto J, Oudejans, Joost J, and Meijer, Chris J L M

Published
2015

28. A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma

Author

de Baaij, Laura R., primary, Berkhof, Johannes, additional, van de Water, Jolanda M.W., additional, Sieniawski, Michal K., additional, Radersma, Marijn, additional, Verbeek, Wieke H.M., additional, Visser, Otto J., additional, Oudejans, Joost J., additional, Meijer, Chris J.L.M., additional, Mulder, Chris J.J., additional, Lennard, Anne L., additional, and Cillessen, Saskia A.G.M., additional

Published
2015
Full Text
View/download PDF

31. Bortezomib Restores Defective Apoptosis by Upregulation of Noxa in Enteropathy-Associated T-Cell Lymphoma

Author

de Baaij, Laura R, primary, Radersma, Marijn, additional, van de Water, Jolanda MW, additional, Groot, Kim BJ, additional, Hijmering, Nathalie J, additional, Moesbergen, Laura M, additional, Visser, Otto J, additional, Oudejans, Joost J, additional, Mulder, Chris JJ, additional, Meijer, Chris JLM, additional, and Cillessen, Saskia AGM, additional

Published
2011
Full Text
View/download PDF

36. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography.

Author

Perk, Lars R., Visser, Otto J., Stigter-van Walsum, M., Vosjan, Maria J. W. D., Visser, Gerard W. M., Zijlstra, Josée M., Huijgens, Peter C., and van Dongen, Guus A. M. S.

Subjects
*ZIRCONIUM isotopes, *YTTRIUM isotopes, *POSITRON emission tomography, *RADIOIMMUNOTHERAPY, *NUDE mouse, *MONOCLONAL antibodies, *HODGKIN'S disease
Abstract

To evaluate whether 89Zr can be used as a PET surrogate label for quantification of 90Y-ibritumomab tiuxetan (90Y-Zevalin) biodistribution and dosimetry before myeloablative radioimmunotherapy. Zevalin was labelled with 89Zr by introducing N-succinyldesferal ( N-sucDf) as a second chelate. For comparison of the in vitro stability of 89Zr-Zevalin and 88Y-Zevalin (as a substitute for 90Y), samples were incubated in human serum at 37°C up to 6 days. Biodistribution of 89Zr-Zevalin and 88Y-Zevalin was assessed at 24, 48, 72 and 144 h p.i. by co-injection in nude mice bearing the non-Hodgkin’s lymphoma (NHL) xenograft line Ramos. The clinical performance of 89Zr-Zevalin-PET was evaluated via a pilot imaging study in a patient with NHL, who had undergone [18F]FDG-PET 2 weeks previously. Modification of Zevalin with N-sucDf resulted in an N-sucDf-to-antibody molar ratio of 0.83±0.04. After radiolabelling and purification, the radiochemical purity and immunoreactivity of 89Zr-Zevalin always exceeded 95% and 80%, respectively. 89Zr-Zevalin showed the same stability in serum as 88Y-Zevalin, with a radiochemical purity >95% during a period of 6 days. The co-injected 89Zr-Zevalin and 88Y-Zevalin conjugates showed a very similar biodistribution, except for liver and bone accumulation at 72 and 144 h p.i., which was significantly higher for 89Zr than for 88Y. PET images obtained after injection of 89Zr-Zevalin showed clear targeting of all known tumour lesions. 89Zr-Zevalin and 88Y-Zevalin showed a very similar biodistribution in mice, implying that 89Zr-Zevalin-PET might be well suited for prediction of 90Y-Zevalin biodistribution in a myeloablative setting. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

37. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells

Author

Al-toma, Abdulbaqi, Visser, Otto J., van Roessel, Hyacintha M., von Blomberg, B. Mary E., Verbeek, Wieke H. M., Scholten, Petra E. T., Ossenkoppele, Gert J., Huijgens, Peter C., and Mulder, Chris J. J.

Abstract

Autologous hematopoietic stem cell transplantation (ASCT) is an increasingly accepted treatment for refractory autoimmune diseases. Refractory celiac disease with aberrant T cells (RCD type II) is unresponsive to available therapies and carries a high risk of transition into enteropathy associated T-cell lymphoma (EATL). This study reports on the feasibility, safety, and efficacy of ASCT in patients with RCD type II. Thirteen patients with RCD type II were evaluated. Seven patients (4 men, 3 women, mean age 61.5 years [range, 51-69 years]) underwent transplantation. After conditioning with fludarabine and melphalan, ASCT was performed. Patients were monitored for response, adverse effects, and hematopoietic reconstitution. All 7 patients completed the mobilization and leukapheresis procedures successfully and subsequently underwent conditioning and transplantation. Engraftment occurred in all patients. No major nonhematologic toxicity or transplantation-related mortality was observed. There was a significant reduction in the aberrant T cells in duodenal biopsies associated with improvement in clinical well-being and normalization of hematologic and biochemical markers (mean follow-up, 15.5 months; range, 7-30 months). One patient died 8 months after transplantation from progressive neuroceliac disease. These preliminary results showed that high-dose chemotherapy followed by ASCT seems feasible and safe and might result in long-term improvement of patients with RCD type II whose condition did not respond promptly to available drugs.

Published
2007
Full Text
View/download PDF

38. Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.

Author

Wondergem, Marielle J., Zijlstra, Josee M., de Rooij, Madelon, Visser, Otto J., Huijgens, Peter C., and Zweegman, Sonja

Subjects
HODGKIN'S disease, B cells, STEM cell transplantation, DRUG therapy, DRUG utilization, THERAPEUTICS
Abstract

The article discusses the Improvement of survival in patients with transformed B cell non Hodgkin lymphoma (NHL), consolidation with Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation. It states that high dose chemotherapy followed by autologous stem cell transplantation (AuSCT) in patients with histologically transformed B cell NHL.

Published
2012
Full Text
View/download PDF

39. Surgery in (pre)malignant celiac disease.

Author

van de Water JM, Nijeboer P, de Baaij LR, Zegers J, Bouma G, Visser OJ, van der Peet DL, Mulder CJ, and Meijerink WJ

Subjects
Aged, Antineoplastic Agents therapeutic use, Celiac Disease diagnosis, Celiac Disease drug therapy, Celiac Disease mortality, Chemotherapy, Adjuvant, Elective Surgical Procedures, Enteropathy-Associated T-Cell Lymphoma diagnosis, Enteropathy-Associated T-Cell Lymphoma drug therapy, Enteropathy-Associated T-Cell Lymphoma mortality, Female, Humans, Intestinal Neoplasms diagnosis, Intestinal Neoplasms drug therapy, Intestinal Neoplasms mortality, Kaplan-Meier Estimate, Male, Middle Aged, Netherlands, Postoperative Complications etiology, Precancerous Conditions diagnosis, Precancerous Conditions drug therapy, Precancerous Conditions mortality, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Celiac Disease surgery, Digestive System Surgical Procedures adverse effects, Digestive System Surgical Procedures mortality, Enteropathy-Associated T-Cell Lymphoma surgery, Intestinal Neoplasms surgery, Precancerous Conditions surgery
Abstract

Aim: To report the outcome of surgery in patients with (pre)malignant conditions of celiac disease (CD) and the impact on survival., Methods: A total of 40 patients with (pre)malignant conditions of CD, ulcerative jejunitis (n = 5) and enteropathy associated T-cell lymphoma (EATL) (n = 35), who underwent surgery between 2002 and 2013 were retrospectively evaluated. Data on indications, operative procedure, post-operative morbidity and mortality, adjuvant therapy and overall survival (OS) were collected. Eleven patients with EATL who underwent chemotherapy without resection were included as a control group for survival analysis. Patients were followed-up every three months during the first year and at 6-mo intervals thereafter., Results: Mean age at resection was 62 years. The majority of patients (63%) underwent elective laparotomy. Functional stenosis (n = 13) and perforation (n = 12) were the major indications for surgery. In 70% of patients radical resection was performed. Early postoperative complications, mainly due to leakage or sepsis, occurred in 14/40 (35%) of patients. Eight patients required reoperation. More patients who underwent resection in the acute setting (n = 3, 20%) died compared to patients treated in the elective setting. With a median follow-up of 20 mo, seven patients (18%) required reoperation due to long-term complications. Significantly more patients who underwent acute surgery could not be treated with adjuvant chemotherapy. Patients who first underwent surgical resection showed significantly better OS than patients who received chemotherapy without resection., Conclusion: Although the complication rate is high, the preferred first step of treatment in (pre)malignant CD consists of local resection as early as possible to improve survival.

Published
2015
Full Text
View/download PDF

40. ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.

Author

Cillessen SA, Hijmering NJ, Moesbergen LM, Vos W, Verbrugge SE, Jansen G, Visser OJ, Oudejans JJ, and Meijer CJ

Subjects
Anaplastic Lymphoma Kinase, Female, Humans, Male, Tumor Cells, Cultured, Bortezomib pharmacology, Gene Expression Regulation, Neoplastic drug effects, Lymphoma, Large-Cell, Anaplastic drug therapy, Lymphoma, Large-Cell, Anaplastic metabolism, Lymphoma, Large-Cell, Anaplastic pathology, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Receptor Protein-Tyrosine Kinases, Up-Regulation drug effects, bcl-2-Associated X Protein biosynthesis
Published
2015
Full Text
View/download PDF

41. Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.

Author

Wondergem MJ, Zijlstra JM, de Rooij M, Visser OJ, Huijgens PC, and Zweegman S

Subjects
Antibodies, Monoclonal therapeutic use, Carmustine therapeutic use, Combined Modality Therapy, Cytarabine therapeutic use, Etoposide therapeutic use, Humans, Melphalan therapeutic use, Treatment Outcome, Yttrium Radioisotopes therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Transplantation, Lymphoma, B-Cell radiotherapy, Radioimmunotherapy methods
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results